CN101879255B - 一种治疗冻伤和具有融血栓功能的药物制剂 - Google Patents
一种治疗冻伤和具有融血栓功能的药物制剂 Download PDFInfo
- Publication number
- CN101879255B CN101879255B CN2010102161885A CN201010216188A CN101879255B CN 101879255 B CN101879255 B CN 101879255B CN 2010102161885 A CN2010102161885 A CN 2010102161885A CN 201010216188 A CN201010216188 A CN 201010216188A CN 101879255 B CN101879255 B CN 101879255B
- Authority
- CN
- China
- Prior art keywords
- melting
- cold injury
- pharmaceutical preparation
- treatment
- fructus jujubae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 title abstract description 24
- 208000001034 Frostbite Diseases 0.000 title abstract 3
- 230000002537 thrombolytic effect Effects 0.000 title abstract 3
- 208000009084 Cold Injury Diseases 0.000 claims description 30
- 208000007536 Thrombosis Diseases 0.000 claims description 30
- 230000002595 cold damage Effects 0.000 claims description 30
- 230000008018 melting Effects 0.000 claims description 23
- 238000002844 melting Methods 0.000 claims description 23
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- 206010028748 Nasal obstruction Diseases 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 206010056377 Bone tuberculosis Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗冻伤和具有融血栓功能的药物制剂涉及一种中药制剂，特别涉及用于治疗冻伤，还具有融血栓功效的药物制剂，本发明由以下组份的中药材构成：大枣100g-200g，雪莲花30g-70g，枸杞50-150g，藏红花15-40g，杜仲80-120g和甘草15-30g。本发明配伍合理，效果明显。
Description
技术领域
本发明涉及一种中药制剂，特别涉及用于治疗冻伤，还具有融血栓功效的药物制剂。
背景技术
随着人们生活水平的不断提高，人们对生活质量的要求也越来越高，同时，由于人们对生活的日常起居饮食安排存在着不合理，使很多现代疾病产生和盛行的机会也越来越大，如高血压、高血脂、脑血栓等疾病的盛行严重威胁着人们的身体健康，因此人们在不断提高生活质量的同时，也日益注重自己的身体健康，如何有效预防疾病就成为人们关注的重点。目前市场上的融血栓的保健食品质量和效果参差不齐，且多数以单纯的补充营养为主，预防保健的效果并不理想。
而冻伤则是由于寒冷作用引起的人体组织损伤，通常在温度较的情况下发生，冻狎后，身体局部血液循环不畅，血管收缩而致使人体组织损伤。目前的中医多以单味中药配成各种制剂外敷，但由于制剂组方不同，且多是外用，疗效较弱，起效缓慢。
发明内容
本发明的目的旨在于克服现有技术的缺陷，提供一种具有融血栓功能之外，还对冻伤具有较好治疗效果的治疗冻伤和具有融血栓功能的药物制剂。
本发明所述的一种治疗冻伤和具有融血栓功能的药物制剂，由以下组份的中药材构成的组合物：大枣100g-200g，雪莲花30g-70g，枸杞50-150g，藏红花15-40g，杜仲80-120g和甘草15-30g。
所述的治疗冻伤和具有融血栓功能的药物制剂，采收6～7月间开花的雪莲花，拔起全株，除去泥沙，晾干备用；大枣除去杂质，洗净，晒干，破开备用；将上述重量的雪莲花、大枣、枸杞、藏红花杜仲及甘草的组合物用50度以上的白酒浸泡，常温常压下浸泡至少6个月即可。所述的药物组合物与白酒的重量份比为1∶10-15。
本发明所述的治疗冻伤和具有融血栓功能的药物制剂，可用于治疗冻伤，取适量外用，并于晚上睡前内服，服用量为10-30ml/日。
本发明所述的治疗冻伤和具有融血栓功能的药物制剂，可用于融血栓治疗，于晚上睡前内服，服用量为10-30ml/日。
本发明所述的治疗冻伤和具有融血栓功能的药物制剂，可用于治疗鼻塞，于晚上睡前内服，服用量为10-30ml/日。
本发明中，藏红花的干燥柱头味甘性平，能活血化瘀，散郁开结，止痛。用于治疗忧思郁结，胸膈痞闷，吐血，伤寒发狂，惊怖恍惚，妇女经闭，血滞月经不调，产后恶露不尽，瘀血作痛，麻疹，跌打损伤等。外用作镇静、驱风剂。活血化瘀，凉血解毒，解郁安神。温毒发斑、忧郁痞闷、惊悸发狂。藏红花具有显著的抗血凝作用。其所含有的腺苷是抑制血小板聚集的活性成分为，能延长血浆凝血酶原时间及活化部分凝血活酶时间(aPTT)，抑制ADP和胶原诱导的血小板聚集，加速尿激酶及纤维蛋白溶酶的纤溶作用。体外(终浓度为87mg/ml)亦能抑制ADP诱导的大鼠血小板聚集。能抑制血小板聚集，减轻炎症反应，使肾毛细血管扩张，增加肾血流量，促进免疫复合物吸收和炎症损害的修复。雪莲花具有生理活性有效成分。其中伞形花内酯具有明显的抗菌、降压镇静、解痉作用；东莨菪素具有祛风、抗炎、止痛、祛痰和抗肿瘤作用，芹菜素具有平滑肌解痉和抗胃溃疡作用；对羚基苯酮有明显的利胆作用。雪莲花中所含的秋水仙碱，该成分是细胞有丝分裂的一个典型代表，能抑制癌细胞的增长，对痛风急性发作特异功效，12-24小时内减轻炎症并迅速止痛，长期使用可减少发作次数。杜仲具有降血压、补肝肾，强筋骨，安胎气的功效。适用于：肝肾亏虚：证见眩晕、腰膝酸痛、筋骨痿弱等。多见于高血压病、眩晕症、脑血管意外后遗症、慢性肾脏疾病、脊髓灰质炎等。肾气不固：证见尿频或尿有余沥、阴下湿痒、阳痿、孕妇体弱、胎动不安或腰坠痛等。多见于慢性前列腺疾病、性功能障碍、不育症、先兆流产或习惯性流产等。也可以用于慢性关节疾病、骨结核、痛经、功能失调性子宫出血、慢性盆腔炎等疾病而出现肝肾亏虚征候者。大枣的现代药理研究表明具增加白血球内的cAMP的作用，具有抗变态反应、保肝、增加肌力、镇静、催眠和降压的作用的免疫抑制作用：大枣的醇提物以每天100mg给大鼠灌胃，显示大枣与硫唑嘌呤具有同样的免疫抑制作用，对特异反应性疾病能抑制抗体的产生。大枣醇提物可能对大鼠反应性抗体有抑制作用，而对非反应性抗体不产生抑制作用。此外，大枣中的黄酮双葡萄糖苷A，药理实验证明有镇静、催眠和降压作用，大枣有增加白血球内cAMP的作用。大枣煎剂能降低CC14对家兔肝脏的损伤。能延长小鼠的游泳时间。最近报道大枣有抑制癌细胞的增殖作用。枸杞具有滋补肝肾，益精明目。用于虚劳精亏，腰膝酸痛，眩晕耳鸣，内热消渴，血虚萎黄，目昏不明的功效，具有有增强非特异性免疫作用，能增强血清溶菌酶的作用，提高血清中抗绵羊红细胞抗体的效价，还能增加鼠脾脏中抗绵羊红细胞的抗体形成细胞的数量。且枸杞可显著而持久降低大鼠血糖，增加糖耐量，且毒性较小。另外，本品还有抗肿瘤、促进造血功能等作用。而甘草具有补脾益气，清热解毒，祛痰止咳，缓急止痛，调和诸药的功效。用于脾胃虚弱，倦怠乏力，心悸气短，咳嗽痰多，脘腹、四肢挛急疼痛，痈肿疮毒，缓解药物毒性、烈性。
本发明中藏红花的味甘性平，具有活血化瘀，散郁开结，止痛的功效，可用于凉血解毒，解郁安神，治疗忧思郁结，胸膈痞闷，吐血，伤寒发狂，惊怖恍惚，妇女经闭，血滞月经不调，产后恶露不尽，瘀血作痛，麻疹，跌打损伤等。外用则可镇静、驱风。活血化瘀。雪莲花甘苦，温，入肝、脾、肾三经。含云香甙，雪莲内脂，生物碱，挥发油，多糖。具有除寒，壮阳，调经，止血的功效。主要用于治阳痿，腰膝软弱，妇女崩带，月经不调，风湿性关节炎，外伤出血。藏红花与雪莲花相佐，可行气活血，辅以杜仲的补肝肾、强筋骨、调节血压功效，从而达到消融血栓的功能，此外本发明中还配以枸杞，枸杞具有补肾益精，养肝明目，补血安神，生津止渴，润肺止咳的功效。可用于治疗治肝肾阴亏，腰膝酸软，头晕，目眩，目昏多泪，虚劳咳嗽，消渴，遗精，辅以大枣性质平和，是适用于老年人的安全、有效的药物。大枣益气生津，尤可治疗老年人气血津液不足。本方中以甘草调和诸药，共凑融血栓、治冻疮的效果，本发明还可用于鼻炎或感冒所引起的鼻塞。本发明配伍合理，效果明显。
具体实施方式
下面结合实施例对本发明作进一步的说明，但不限于实施例。
实施例1
一种治疗冻伤和具有融血栓功能的药物制剂，其特征在于，由以下组份的中药材构成：大枣100g，雪莲花30g，枸杞50g，藏红花15g，杜仲80g，甘草15g。采收6～7月间开花的雪莲花，拔起全株，除去泥沙，晾干备用；大枣除去杂质，洗净，晒干，破开备用；将雪莲花、大枣、枸杞、藏红花杜仲及甘草用3000g白酒浸泡，白药为50度的白酒浸泡至少6个月即可。
实施例2
一种治疗冻伤和具有融血栓功能的药物制剂，其特征在于，由以下组份的中药材构成：大枣100g，雪莲花50g，枸杞100g，藏红花30g，杜仲100g 甘草20g。采收6～7月间开花的雪莲花，拔起全株，除去泥沙，晾干备用；大枣除去杂质，洗净，晒干，破开备用；将雪莲花、大枣、枸杞、藏红花杜仲及甘草用50度以上的白酒5000g浸泡至少6个月即可。
实施例3
一种治疗冻伤和具有融血栓功能的药物制剂，其特征在于，由以下组份的中药材构成：大枣200g，雪莲花70g，枸杞150g，藏红花40g，杜仲120g 甘草30g。采收6～7月间开花的雪莲花，拔起全株，除去泥沙，晾干备用；大枣除去杂质，洗净，晒干，破开备用；将雪莲花、大枣、枸杞、藏红花杜仲及甘草用50度以上的白酒9000g浸泡至少6个月即可。
实施例4
本发明所述的治疗冻伤和具有融血栓功能的药物制剂，可内服和外用，治疗冻伤时，用棉签沾取适量药酒涂于患处，并于晚上睡前内服，服用量为10-30ml/日。患者100例，其中1度冻伤50例，2度冻伤50例，每日早晨用本发明所述的治疗冻伤和具有融血栓功能的药酒涂于患处，于睡前服用10ml，7-10天后，1度冻伤全部愈合，2度冻伤冻伤愈合49例，愈合率为99％。
实施例5
本发明所述的治疗冻伤和具有融血栓功能的药物制剂，用于融血栓治疗时，于晚上睡前内服，服用量为10-30ml/日。血栓患者50例，每日睡觉前分三次服用30ml的药酒，90-120天后，经检查小的血栓被完全溶解和吸收；大的血栓则被部分溶解而软化，有效率达98％。
实施例6
本发明所述的治疗冻伤和具有融血栓功能的药物制剂，用于治疗鼻塞时，于晚上睡前内服，服用量为10-30ml/日，也可用棉签沾取适量药酒涂于鼻腔内部。患者20例，10例过敏性流涕，10例鼻炎流涕，于每日睡前用棉签沾取适量药酒涂于鼻腔内部，重症者再口服10ml，3-7日症状明显减轻和好转。
Claims (5)
1.一种治疗冻伤和具有融血栓功能的药物制剂，其特征在于，由以下组份的中药材构成：大枣100g-200g，雪莲花30g-70g，枸杞50-150g，藏红花15-40g，杜仲80-120g和甘草15-30g，采收6～7月间开花的雪莲花，拔起全株，除去泥沙，晾干备用；大枣除去杂质，洗净，晒干，破开备用；将雪莲花、大枣、枸杞、藏红花、杜仲及甘草用50度以上的白酒浸泡，常温常压下浸泡至少6个月即得制剂。
2.根据权利要求1所述的治疗冻伤和具有融血栓功能的药物制剂，其特征在于，所述的药物组合物与白酒的重量份比为1∶10-15。
3.根据权利要求1所述的治疗冻伤和具有融血栓功能的药物制剂，其特征在于，用于治疗冻伤，取适量外用，并于晚上睡前内服，服用量为10-30ml/日。
4.根据权利要求1所述的治疗冻伤和具有融血栓功能的药物制剂，其特征在于，用于融血栓治疗，于晚上睡前内服，服用量为10-30ml/日。
5.根据权利要求1所述的治疗冻伤和具有融血栓功能的药物制剂，其特征在于，用于治疗鼻塞，于晚上睡前内服，服用量为10-30ml/日。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102161885A CN101879255B (zh) | 2010-07-02 | 2010-07-02 | 一种治疗冻伤和具有融血栓功能的药物制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102161885A CN101879255B (zh) | 2010-07-02 | 2010-07-02 | 一种治疗冻伤和具有融血栓功能的药物制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101879255A CN101879255A (zh) | 2010-11-10 |
| CN101879255B true CN101879255B (zh) | 2012-01-04 |
Family
ID=43051484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102161885A Expired - Fee Related CN101879255B (zh) | 2010-07-02 | 2010-07-02 | 一种治疗冻伤和具有融血栓功能的药物制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101879255B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055833A (zh) * | 2013-03-21 | 2014-09-24 | 刘宝英 | 一种美白祛斑的食疗组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1151877A (zh) * | 1995-12-12 | 1997-06-18 | 黄吉文 | 一种药酒及其制备方法 |
| CN101057914A (zh) * | 2006-08-18 | 2007-10-24 | 聂钢峰 | 一种治疗腰椎间盘突出、阳痿、早泄、胃炎及妇科病的药酒及配制方法 |
| CN101642548B (zh) * | 2009-08-27 | 2011-05-18 | 吴玉平 | 治疗腰腿疼痛的中药膏贴及其制备方法 |
-
2010
- 2010-07-02 CN CN2010102161885A patent/CN101879255B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101879255A (zh) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078555B (zh) | 治疗偏头痛的中药 | |
| CN103405596A (zh) | 一种治疗鼻窦炎的中药 | |
| CN101879301A (zh) | 一种治疗慢性宫颈炎的中草药制剂 | |
| CN103182064A (zh) | 一种治疗风寒咳嗽的药物及其制备方法 | |
| CN103100016B (zh) | 一种治疗皮肤瘙痒症的中药 | |
| CN101879255B (zh) | 一种治疗冻伤和具有融血栓功能的药物制剂 | |
| CN100387291C (zh) | 一种治疗肺结核的药物 | |
| CN103071076B (zh) | 一种足浴护理促进剖宫产术后恢复的中药组合物及应用 | |
| CN102247504B (zh) | 一种化疣散剂的制备方法 | |
| CN104225339A (zh) | 一种治疗慢性肺炎的中药制剂及制备方法 | |
| CN104257883A (zh) | 一种治疗化疗后白细胞减少症的中药组合物 | |
| CN100546617C (zh) | 一种治疗输卵管阻塞性不孕症的中药制剂 | |
| CN106728002A (zh) | 一种治疗跌打损伤的药酒 | |
| CN103585263B (zh) | 一种治疗慢性化脓性中耳炎的中药组合物及其制备方法 | |
| CN103463517B (zh) | 治疗哮喘的药物 | |
| CN105267425A (zh) | 一种用于治疗鼻炎的滴鼻剂及其制备方法 | |
| CN105343346A (zh) | 一种治疗外阴瘙痒的中药片剂及其制备方法 | |
| CN105031380A (zh) | 一种用于孕妇口腔局部麻醉的药物及其制备方法 | |
| CN103041085A (zh) | 一种足浴护理治疗痛经的中药组合物及应用 | |
| CN102846699B (zh) | 一种治疗缺血性中风的中药组合物及其制备工艺 | |
| CN1238012C (zh) | 一种治疗牙痛、口腔疾病的药物 | |
| CN106038905A (zh) | 一种麻醉止痛药物及其制备方法 | |
| CN105853712A (zh) | 一种治疗眼科疾病的中药组合物 | |
| CN104758346A (zh) | 一种治疗偏头痛的药物及其制备方法、制剂 | |
| CN104189154B (zh) | 一种治疗病毒性结膜炎的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN JINBI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHOU YUNFEI Effective date: 20130217 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 651600 CHUXIONG YI AUTONOMOUS PREFECTURE, YUNNAN PROVINCE TO: 675400 CHUXIONG YI AUTONOMOUS PREFECTURE, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130217 Address after: 675400, Chuxiong, Yi Autonomous Prefecture of Yunnan province Dayao County town, No. 6 Ring Road North Patentee after: Yunnan Jinbi Pharmaceutical Co., Ltd. Address before: 651600, Yunnan County, Wuding province perfume village committee, big wave Ji Long Ji 9 Patentee before: Zhou Yunfei |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 Termination date: 20180702 |